Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Novo Nordisk is progressing both subcutaneous and ... will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031.

For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...

The stock market heads into the final week of June with an eye on Tesla, Novo Nordisk, defense stocks and weekly jobless ...

Wednesday marked a losing session on Wall Street, with the S&P 500 snapping its three-day win streak, as did the Nasdaq ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...